ANALYSIS OF GOVERNMENT PROCUREMENTS OF MEDICINES APPLIED IN RARE DISEASES THERAPY
Abstract
the article presents the results of analysis of the state procurement of the drugs for rare diseases. The analysis was conducted on the basis of 1499 selected trade procedures on rare disease drugs procurement in 2013. The article evaluates the state of competition in procurement of monopoly and alternative drugs, the level of price reduction as a result of trading, the amount and volume of purchases in the subjects of the Russian Federation. The analysis results show that tender procedures used for the procurement of monopoly drugs are ineffective because of the lack of competition; distributors are not interested in price reduction at noncompetitive procedures. In the procurement of alternative drugs at competitive trade procedures it is possible to reach a high level of price reduction, indicating overpricing of the initial (maximum) contract price of procured drugs.
About the Authors
D. V. Fedyaev
Russian Presidential Academy of National Economy and Public Administration, Federal State Educational Institution of Higher Professional Education, Moscow
Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution, Moscow
Russian Federation
Russian Federation
V. K. Fedyaeva
Russian Presidential Academy of National Economy and Public Administration, Federal State Educational Institution of Higher Professional Education, Moscow
Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution, Moscow
Russian Federation
Russian Federation
V. V. Omelyanovsky
Russian Presidential Academy of National Economy and Public Administration, Federal State Educational Institution of Higher Professional Education, Moscow
Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution, Moscow
Russian Federation
Russian Federation
References
1. Report on the evaluation of the availability of drugs on the basis of the analysis of consumer prices and pricing of drugs in the Russian Federation (including in the context of the Russian Federation) and in comparable markets countries, including those from the CIS, the European Union and the BRICS, FAS Russia, 2013 [Doklad o rezul'tatakh otsenki dostupnosti lekarstvennykh preparatov na osnove analiza potrebitel'skikh tsen i tsenoobrazovaniya na lekarstvennye preparaty v Rossiiskoi Federatsii (v tom chisle v razreze sub»ektov Rossiiskoi Federatsii) i na sopostavimykh rynkakh stran, v tom chisle vkhodyashchikh v SNG, Evropeiskii soyuz i BRIKS, FAS Rossii, 2013]. URL http://www.fas.gov.ru/analytical-materials/analytical-materials_31072.html
2. Kradinov P.G. Nauchno-issledovatel'skii finansovyi institut. Finansovyi zhurnal. 2013; 3 (17): 37-46.
3. Omel'yanovskii V.V., Sura M.V., Gerasimova K.V., Avksent'eva M.V., Tatarinov A.P. Assessment of the necessary financial costs medicinal maintenance of patients with rare diseases in Russia. Newsletter. Expert Health Council of the Federation Council Committee on Social Policy of the Federal Assembly of the Russian Federation [Otsenka neobkhodimykh finansovykh zatrat na lekarstvennoe obespechenie bol'nykh s redkimi zabolevaniyami v RF. Informatsionnyi byulleten'. Ekspertnyi sovet po zdravookhraneniyu komiteta Soveta Federatsii po sotsial'noi politike Federal'nogo Sobraniya RF]. 2014.
4. The decision of the Government of the Russian Federation of 26.04.2012 No 403 «On the order of the Federal Register of persons suffering from life-threatening and chronic progressive rare (orphan) diseases that can shorten life expectancy of citizens or their disability and its regional segment» [Postanovlenie Pravitel'stva Rossiiskoi Federatsii ot 26.04.2012 No 403 «O poryadke vedeniya Federal'nogo registra lits, stradayushchikh zhizneugrozhayushchimi i khronicheskimi progressiruyushchimi redkimi (orfannymi) zabolevaniyami, privodyashchimi k sokrashcheniyu prodolzhitel'nosti zhizni grazhdan ili ikh invalidnosti, i ego regional'nogo segmenta»].
5. Rebrova O.Yu. Statistical analysis of medical data. Application software package STATISTICA [Statisticheskii analiz meditsinskikh dannykh. Primenenie paketa prikladnykh programm STATISTICA]. Moscow. 2002; 312 s.
6. Federal Law of 04.06.2014 No 140-FZ On Amendments to the Federal Law «On the contract system in the procurement of goods, works and services for state and municipal needs» [Federal'nyi zakon ot 04.06.2014 No 140-FZ O vnesenii izmenenii v Federal'nyi zakon «O kontraktnoi sisteme v sfere zakupok tovarov, rabot, uslug dlya obespecheniya gosudarstvennykh i munitsipal'nykh nuzhd»].
7. Federal Law of 05.04.2013 No 44-FZ «On the contract system in the procurement of goods, works and services for state and municipal needs» [Federal'nyi zakon ot 05.04.2013 No 44-FZ «O kontraktnoi sisteme v sfere zakupok tovarov, rabot, uslug dlya obespecheniya gosudarstvennykh i munitsipal'nykh nuzhd»].
8. The Federal Law of 21.07.2005 No 94-FZ «On placing orders for goods, works and services for state and municipal needs» [Federal'nyi zakon ot 21.07.2005 No 94-FZ «O razmeshchenii zakazov na postavki tovarov, vypolnenie rabot, okazanie uslug dlya gosudarstvennykh i munitsipal'nykh nuzhd»].
9. Fedyaev D.V., Maksimova L.V., Omel'yanovskii V.V. Meditsinskie tekhnologii. Otsenka i vybor. 2014; 1: 57-64.
10. Shakhova G.Ya., Kradinov P.G. Nauchno-issledovatel'skii finansovyi institut. Finansovyi zhurnal. 2012; 3: 15-28.
For citation:
Fedyaev D.V., Fedyaeva V.K., Omelyanovsky V.V. ANALYSIS OF GOVERNMENT PROCUREMENTS OF MEDICINES APPLIED IN RARE DISEASES THERAPY. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2014;7(4):3-10. (In Russ.)
Views: 1248
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 